Cencora, Inc. $COR Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cencora, Inc. (NYSE:COR) by 13.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,270 shares of the company’s stock after buying an additional 5,543 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Cencora were worth $15,086,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares during the last quarter. Norges Bank purchased a new stake in shares of Cencora during the 2nd quarter valued at $695,215,000. Viking Global Investors LP grew its stake in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the period. Finally, Amundi increased its holdings in shares of Cencora by 17.0% during the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after buying an additional 249,742 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on COR shares. Barclays began coverage on Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price on the stock. Wells Fargo & Company lifted their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $415.00 price target on shares of Cencora in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $393.08.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is currently owned by insiders.

Cencora Stock Performance

Shares of NYSE:COR opened at $359.14 on Friday. The business’s 50-day simple moving average is $347.62 and its 200 day simple moving average is $323.87. The company has a market cap of $69.67 billion, a P/E ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a one year low of $237.71 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the company earned $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s payout ratio is 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.